187
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d15059184e193">Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). </p>

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          New England Journal of Medicine (NEJM/MMS)
          0028-4793
          1533-4406
          November 10 2016
          November 10 2016
          : 375
          : 19
          : 1823-1833
          Article
          10.1056/NEJMoa1606774
          27718847
          092ce6ff-7b40-45e7-9467-b1499064320c
          © 2016
          History

          Comments

          Comment on this article